lundi 12 novembre 2018

Onco Actu du 12 novembre 2018

3.1 Prévention - Tabac

F.D.A. Plans to Seek a Ban on Menthol Cigarettes [NY Times]

3.4 Chimioprévention

Vitamin D And Fish Oil Supplements Mostly Disappoint In Long-Awaited Research Results [NPR]

Vitamin D and Fish Oils Are Ineffective for Preventing Cancer and Heart Disease [NY Times]

4.9 Dép., diag. & prono. - Sein

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years [Queen Mary University of London]

Government funds trial of artificial intelligence to help with breast cancer screenings [The Telegraph]

5.12 Immunothérapies

Radiotherapy-induced Responses Enhance the Efficacy of Anti-CTLA4 Therapy in Chemo-refractory Metastatic NSCLC [ESMO]

5.12.3 Immunothérapies-combinaisons

The latest update on NKTR-214/Opdivo from Nektar and Bristol-Myers will keep the controversy burning over the ORR rate [EndPoints]

5.12.9 Immunothérapies - SITC

New Data From Investigational Study Of Lenvima® (Lenvatinib) And Keytruda® (Pembrolizumab) Combination In Three Different Tumor Types Presented At The Society For Immunotherapy Of Cancer’s 33rd Annual Meeting [Eisai]

SITC18: Aduro finds some activity with STING agonist [FierceBiotech]

Aduro Biotech Presents Preliminary Results from Ongoing Phase 1 Trials of STING agonist ADU-S100 (MIW815) in Patients with Advanced Solid Tumors or Lymphomas [Aduro]

TESARO Announces Immuno-Oncology Data Presentations at SITC 2018 Annual Meeting [Tesaro]

SITC 2018 Scientific Highlights - Nov. 9 [SITC]

SITC 2018 Scientific Highlights - Nov. 10 [SITC]

#SITC18: Another underwhelming performance for STING damages Aduro’s already suffering share price [EndPoints]

5.2 Pharma

US FDA accepts regulatory submission for Lynparza maintenance therapy in newly-diagnosed, BRCA-mutated advanced ovarian cancer and grants Priority Review [AstraZeneca]

As Novartis' other cancer launches struggle, Lutathera gets off to flying start [FiercePharma]

5.4 Traitements - Economie

Eisai's Lenvima wins over NICE in liver cancer in just three months [Pharmafile]

6.3 Associations/Fondations

Billionaire gifts Harvard a historic $200M to ‘expedite’ translational biomedical research work [EndPoints]

6.6 Publications

Reaction of Researchers to Plan S: Too Far, Too Risky [Plan S Open Letter]

6.7 DMP, Big Data & applis

Why Did Google Hire Geisinger CEO Dr. David Feinberg? [Forbes]

6.7.1 IA/bioinformatique

AI Doesn't Ask Why -- But Physicians And Drug Developers Want To Know [Forbes]

6.9 Controverses

What’s in a p value? [Vantage]